Ocriplasmin (Jetrea®; ThromboGenetics, Inc.; Iselin, New Jersey) recently burst onto the scene to aid in the treatment of vitreomacular adhesion (VMA). Ocriplasmin gained US Food and Drug ...

A single intravitreal injection of a biologic agent effectively resolved vitreomacular traction and closed macular holes without surgery, according to a study. Perspective from Pravin U. Dugel, MD ...

Ocriplasmin for the treatment of symptomatic vitreomacular adhesion (VMA) is linked to visual impairment, according to 2 case reports published online February 27 in JAMA Ophthalmology. One expert ...

In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to improve vision ...

If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole Leuven, Belgium - 23 December, 2011 - ThromboGenics NV ...

A study published by the German EXPORT study group came to reassuring conclusions concerning vitrectomy surgery in eyes in which previous ocriplasmin treatment for macular hole has failed. The ...

To describe a survey of the use of ocriplasmin by members of the British and Eire Association of VitreoRetinal Surgeons (BEAVRS) for VitreoMacular Traction (VMT) and Full Thickness Macular Hole (FTMH) ...

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces that it has submitted a Biologics License Application (BLA) with the US Food and Drug ...

Leuven, Belgium, 16 August 2017 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that further ocriplasmin ...

Stalmans et al. (Aug. 16 issue) 1 report that intravitreal injection of ocriplasmin was superior to injection of placebo in altering the vitreoretinal interface of affected eyes. It was associated ...

If approved, ocriplasmin will be the first pharmacological treatment for symptomatic vitreomacular adhesion (VMA) including macular hole ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical ...